{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:09:18Z","timestamp":1788822558699,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semarthrit.2025.152647","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T16:26:52Z","timestamp":1738168012000},"page":"152647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Are participants in gout medication registration clinical trials representative of people with gout in the general population?"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7910-0910","authenticated-orcid":false,"given":"Jendy","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152647_bib0001","series-title":"Step 3: clinical research. [Internet]","year":"2018"},{"issue":"14","key":"10.1016\/j.semarthrit.2025.152647_bib0002","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMp2215609","article-title":"Why diverse clinical trial participation matters","volume":"388","author":"Schwartz","year":"2023","journal-title":"N Engl J Med"},{"issue":"9453","key":"10.1016\/j.semarthrit.2025.152647_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152647_bib0004","first-page":"1923","article-title":"Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout","volume":"32","author":"Alvarez-Nemegyei","year":"2005","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152647_bib0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152647_bib0006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.rdc.2020.07.008","article-title":"Gender and ethnic inequities in gout burden and management","volume":"46","author":"Guill\u00e9n","year":"2020","journal-title":"Rheum Dis Clin"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152647_bib0007","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1016\/j.numecd.2021.09.011","article-title":"Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs","volume":"31","author":"Fogacci","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152647_bib0008","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152647_bib0009","unstructured":"NHANES. National Health and Nutrition Examination Survey Homepage [Internet]. [cited 2023 August 2]. Available from: https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm."},{"key":"10.1016\/j.semarthrit.2025.152647_bib0010","unstructured":"U.S. Food and Drug Administration. US Food and Drug Administration [Internet]. [cited 2023 August 2]. Available from: https:\/\/www.fda.gov\/."},{"key":"10.1016\/j.semarthrit.2025.152647_bib0011","unstructured":"Clinical Research and Drug Information. CenterWatch [Internet]. [cited 2023 August 2]. Available from: https:\/\/www.centerwatch.com\/."},{"key":"10.1016\/j.semarthrit.2025.152647_bib0012","unstructured":"Drugs@FDA: FDA-approved drugs [Internet]. [cited 2023 August 2]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"10.1016\/j.semarthrit.2025.152647_bib0013","unstructured":"OpenEpi Menu [Internet]. [cited 2023 August 4]. Available from: https:\/\/openepi.com\/Menu\/OE_Menu.htm."},{"key":"10.1016\/j.semarthrit.2025.152647_bib0014","unstructured":"Bognar M. Normal distribution applet\/calculator [Internet]. Uiowa.edu. [cited 2023 August 15]. Available from: https:\/\/homepage.divms.uiowa.edu\/\u223cmbognar\/applets\/normal.html."},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152647_bib0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a STATA command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152647_bib0016","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152647_bib0017","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","article-title":"Gout and hyperuricaemia in the USA: prevalence and trends","volume":"58","author":"Singh","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152647_bib0027","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.semarthrit.2025.152647_bib0018","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with Allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152647_bib0019","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152647_bib0020","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152647_bib0021","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152647_bib0022","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of Pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152647_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with Allopurinol: a randomized, double-blind, placebo-controlled study in Gout patients with an inadequate response to standard-of-care allopurinol (a US-Based Study)","volume":"69","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152647_bib0024","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152647_bib0025","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152647_bib0026","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152647_bib0028","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008: prevalence of gout and hyperuricemia in the US","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152647_bib0030","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/ar2519","article-title":"Menopause, postmenopausal hormone use and serum uric acid levels in US women \u2013 the Third National Health and Nutrition Examination Survey","volume":"10","author":"Hak","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152647_bib0031","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/ard.2006.051649","article-title":"Sex differences in gout epidemiology: evaluation and treatment","volume":"65","author":"Harrold","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152647_bib0032","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study: figure 1","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152647_bib0033","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-8703(03)00189-3","article-title":"Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure","volume":"146","author":"Masoudi","year":"2003","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152647_bib0034","doi-asserted-by":"crossref","first-page":"678","DOI":"10.12968\/hmed.2010.71.12.678","article-title":"Under-representation of the elderly in cancer clinical trials","volume":"71","author":"Lang","year":"2010","journal-title":"Br J Hosp Med (Lond)"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152647_bib0035","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152647_bib0036","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0735-6757(96)90147-3","article-title":"Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population","volume":"14","author":"Goldberg","year":"1996","journal-title":"Am J Emerg Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152647_bib0037","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1532-5415.2010.03032.x","article-title":"Fighting against age discrimination in clinical trials","volume":"58","author":"Cherubini","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152647_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14745","article-title":"Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review","volume":"2","author":"Strait","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152647_bib0039","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11926-018-0728-2","article-title":"The representation of gender and race\/ethnic groups in randomized clinical trials of individuals with systemic lupus erythematosus","volume":"20","author":"Falasinnu","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152647_bib0040","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152647_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials","volume":"4","author":"Flores","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152647_bib0042","first-page":"630","article-title":"Why African Americans may not be participating in clinical trials","volume":"88","author":"Harris","year":"1996","journal-title":"J Natl Med Assoc"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152647_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.3856","article-title":"Trends in racial and ethnic disparities in barriers to timely medical care among adults in the US, 1999 to 2018","volume":"3","author":"Caraballo","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.semarthrit.2025.152647_bib0044","series-title":"Appendix C, improving representation in clinical trials and research: building research equity for women and underrepresented groups [Internet]","year":"2022"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152647_bib0045","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"Grayson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152647_bib0046","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s10067-019-04520-6","article-title":"Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and\/or high serum uric acid levels: a prospective cohort study","volume":"38","author":"Disveld","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152647_bib0047","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","article-title":"Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study","volume":"20","author":"Roughley","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152647_bib0048","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3945\/ajcn.116.150946","article-title":"The NHANES dietary data are physiologically implausible and inadmissible as scientific evidence","volume":"106","author":"Archer","year":"2017","journal-title":"Am J Clin Nutr"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:52:24Z","timestamp":1741081944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":47,"alternative-id":["S0049017225000186"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152647","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are participants in gout medication registration clinical trials representative of people with gout in the general population?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152647"}}